Improving the Selection of Patients With Glioblastoma Multiforme for Treatment With Epidermal Growth Factor Receptor Inhibitor Therapies.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 21 Jul 2016
At a glance
- Drugs Erlotinib (Primary) ; Gefitinib (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 19 Jul 2016 Status changed from withdrawn prior to enrolment to active, no longer recruiting.
- 26 Jul 2013 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 03 Aug 2012 New source identified and integrated (Mayo Clinic, 1082-05)